PCSK9 Inhibitors Continue To Impress With Efficacy & Safety
Executive Summary
Emerging data on the hotly anticipated PCSK9 inhibitor class show unprecedented declines in LDL cholesterol levels and no signs of the safety issues that plague statins – including myalgia and neurocognitive events.